Stefano Cascinu

Research interests

Publications

• Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

  European Journal of Cancer · 2022 · https://doi.org/10.1016/j.ejca.2022.11.017

• Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

  ESMO Open · 2022 · https://doi.org/10.1016/j.esmoop.2022.100591

• Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.07.004

• The evolving role of microsatellite instability in colorectal cancer: A review

  Cancer Treatment Reviews · 2016 · 10.1016/j.ctrv.2016.10.005

• Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70118-4

• Addressing the challenges of pancreatic cancer: Future directions for improving outcomes

  Pancreatology · 2014 · https://doi.org/10.1016/j.pan.2014.10.001

• VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE‐1 study

  International Journal of Cancer · 2014 · https://doi.org/10.1002/ijc.28772

• Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mdr623

• Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.33.5091

• PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.20.2796

• Randomized Controlled Trial

  Journal · 2009 · https://doi.org/10.1007/978-0-387-78665-0_6514

• Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

  Annals of Oncology · 2008 · https://doi.org/10.1093/annonc/mdn637

• Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial

  The Lancet Oncology · 2008 · https://doi.org/10.1016/s1470-2045(07)70383-2

• Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2007.11.5956

• Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)

  Annals of Oncology · 2006 · https://doi.org/10.1093/annonc/mdl459

• Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies

  Journal of Clinical Oncology · 2004 · https://doi.org/10.1200/jco.2004.00.117

• Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

  Journal of Clinical Oncology · 2002 · 10.1200/jco.2002.07.061

• Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials

  Annals of Oncology · 2000 · 10.1023/a:1008377101672

Current projects

No projects listed.